Cabaletta Bio, Inc. Stock News

DSG3-CAART IND clearance received in October 2019 and Orphan Drug Designation granted by the FDA for the treatment of pemphigus vulgaris (PV) in January 2020; anticipated delay.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...

PHILADELPHIA, Feb. 20, 2020 -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics

Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today

The objective of any investor is a simple one: to make money.While this objective couldn’t be clearer, it is much harder putting it into action. How is one to spot the potential of a stock on a down

PHILADELPHIA, Nov. 26, 2019 -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell.

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported p

PHILADELPHIA, Oct. 25, 2019 -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell.

Low-priced biotech stocks are often targets of pump-and-dump manipulation scams or other activity designed to make money for a select few, not you (think

Cabaletta Bio, a biotech company focused on the development of T cell therapies for B cell-mediated autoimmune diseases, closed a $50m Series B financing

Of all the things that your doctor could tell you that might be a cause for alarm, hearing that you have late-stage cancer is probably one of the worst. We've all heard people talk about a 'cure for c